DK2567690T3 - Anvendelse af amisulphrid til behandling af kemoterapi-induceret kvalme og opkast - Google Patents

Anvendelse af amisulphrid til behandling af kemoterapi-induceret kvalme og opkast

Info

Publication number
DK2567690T3
DK2567690T3 DK12188047.0T DK12188047T DK2567690T3 DK 2567690 T3 DK2567690 T3 DK 2567690T3 DK 12188047 T DK12188047 T DK 12188047T DK 2567690 T3 DK2567690 T3 DK 2567690T3
Authority
DK
Denmark
Prior art keywords
amisulphride
vomiting
chemotherapy
treatment
induced nausea
Prior art date
Application number
DK12188047.0T
Other languages
English (en)
Inventor
Julian Clive Gilbert
Robert William Gristwood
Nicola Cooper
Gabriel Fox
Original Assignee
Acacia Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42136792&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2567690(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acacia Pharma Ltd filed Critical Acacia Pharma Ltd
Application granted granted Critical
Publication of DK2567690T3 publication Critical patent/DK2567690T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK12188047.0T 2010-03-11 2011-03-10 Anvendelse af amisulphrid til behandling af kemoterapi-induceret kvalme og opkast DK2567690T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1004020.2A GB201004020D0 (en) 2010-03-11 2010-03-11 New therapeutic use
EP11709793.1A EP2544657B1 (en) 2010-03-11 2011-03-10 Use of amisulpride for treating post-operative nausea and vomiting

Publications (1)

Publication Number Publication Date
DK2567690T3 true DK2567690T3 (da) 2014-08-11

Family

ID=42136792

Family Applications (3)

Application Number Title Priority Date Filing Date
DK11709793.1T DK2544657T3 (da) 2010-03-11 2011-03-10 Anvendelse af amisulprid til behandling af post-operativ kvalme og opkastning
DK12188047.0T DK2567690T3 (da) 2010-03-11 2011-03-10 Anvendelse af amisulphrid til behandling af kemoterapi-induceret kvalme og opkast
DK14173186.9T DK2796171T3 (da) 2010-03-11 2011-03-10 Anvendelse af amisulprid til behandling af opiat-induceret kvalme og opkastning

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK11709793.1T DK2544657T3 (da) 2010-03-11 2011-03-10 Anvendelse af amisulprid til behandling af post-operativ kvalme og opkastning

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK14173186.9T DK2796171T3 (da) 2010-03-11 2011-03-10 Anvendelse af amisulprid til behandling af opiat-induceret kvalme og opkastning

Country Status (26)

Country Link
US (12) US8686019B2 (da)
EP (3) EP2544657B1 (da)
JP (2) JP5886213B2 (da)
KR (1) KR101738201B1 (da)
CN (1) CN102892407B (da)
AU (1) AU2011225898B2 (da)
BR (1) BR112012022746B1 (da)
CA (1) CA2792392C (da)
CY (3) CY1115487T1 (da)
DK (3) DK2544657T3 (da)
EA (1) EA030335B1 (da)
ES (3) ES2665418T3 (da)
GB (1) GB201004020D0 (da)
HR (3) HRP20140744T1 (da)
HU (1) HUE037088T2 (da)
IL (1) IL221746A (da)
LT (1) LT2796171T (da)
MX (3) MX2012010411A (da)
NO (1) NO2796171T3 (da)
NZ (1) NZ602279A (da)
PL (3) PL2567690T3 (da)
PT (3) PT2567690E (da)
RS (3) RS53466B (da)
SI (3) SI2544657T1 (da)
SM (3) SMT201800188T1 (da)
WO (1) WO2011110854A2 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201004020D0 (en) 2010-03-11 2010-04-21 Acacia Pharma Ltd New therapeutic use
CN104435861A (zh) * 2014-12-22 2015-03-25 济南伟传信息技术有限公司 一种治疗妊娠剧吐的茶
GB201506116D0 (en) 2015-04-10 2015-05-27 Acacia Pharma Ltd Kit and combination therapy for nausea and vomiting
EP3344962A4 (en) 2015-09-02 2019-03-13 California Institute of Technology METHOD AND DEVICE FOR THE SPECTROSCOPIC DETECTION OF LOW CONCENTRATIONS OF SULFUR HYDROGEN GAS
GB201618425D0 (en) * 2016-11-01 2016-12-14 Acacia Pharma Ltd method
GB201702250D0 (en) * 2017-02-10 2017-03-29 Acacia Pharma Ltd Method
CN112236138B (zh) 2017-12-05 2024-05-31 赛诺维信制药公司 晶体形式及其制备方法
AU2018379992B2 (en) 2017-12-05 2022-07-21 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
WO2020247603A1 (en) * 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
CA3142355A1 (en) 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
MX2022001374A (es) * 2019-07-31 2022-03-17 Astellas Pharma Inc Composicion farmaceutica para administracion otica.
BR112023000167A2 (pt) * 2020-07-06 2023-01-31 Acacia Pharma Ltd Terapia de náusea e vômito pós-operatórios
JP2025510741A (ja) 2022-03-21 2025-04-15 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環式ｇｌｐ－１アゴニスト
US20250250269A1 (en) 2022-04-14 2025-08-07 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
CN121002014A (zh) 2022-12-15 2025-11-21 加舒布鲁姆生物公司 具有glp-1激动剂活性的化合物的盐和固体形式
JP2026501285A (ja) 2022-12-22 2026-01-14 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環式ｇｌｐ－１アゴニスト
EP4638455A1 (en) 2022-12-22 2025-10-29 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
KR20250168210A (ko) 2023-02-16 2025-12-02 가셔브룸 바이오, 인크. 헤테로시클릭 glp-1 효능제
US20250019389A1 (en) 2023-06-30 2025-01-16 Gasherbrum Bio, Inc. Heterocyclic agonists
JP2026526054A (ja) 2023-07-13 2026-08-04 アコンカグア・バイオ・インコーポレイテッド 化合物、組成物、および方法
EP4743174A1 (en) 2023-07-13 2026-05-20 Aconcagua Bio, Inc. CALCITONIN AND/OR AMYLIN RECEPTOR ACTIVITY MODULATORS
EP4771001A1 (en) 2023-08-31 2026-07-08 Gasherbrum Bio, Inc. Heteroaryl-heterocycloalkyl-based glp-1 agonists
WO2025137307A1 (en) 2023-12-20 2025-06-26 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2025171341A2 (en) 2024-02-08 2025-08-14 Aconcagua Bio, Inc. Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity
WO2025171340A1 (en) 2024-02-08 2025-08-14 Aconcagua Bio, Inc. The treatment of calcitonin- and/or amylin-receptor associated conditions
TW202600132A (zh) 2024-03-08 2026-01-01 美商安尼波那生物公司 用於治療肥胖症及提高減重之方法
WO2026041075A1 (en) 2024-08-21 2026-02-26 Gasherbrum Bio, Inc. Gpl-1 agonists
WO2026051998A1 (en) 2024-09-04 2026-03-12 Aconcagua Bio, Inc. Compounds, compositions, and methods
WO2026096926A1 (en) 2024-11-01 2026-05-07 Aconcagua Bio, Inc. Compounds, compositions, and methods
WO2026156091A1 (en) 2025-01-15 2026-07-23 Aconcagua Bio, Inc. Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2415099A1 (fr) * 1978-01-20 1979-08-17 Ile De France Nouveaux derives de 4-amino-5-alkylsulfonyl ortho-anisamides, leurs procedes de preparation et leur application comme psychotropes
US6169094B1 (en) * 1998-07-14 2001-01-02 Sanofi-Synthelabo Compositions of (S) (-)-amisulpride
DE10163421A1 (de) 2001-12-21 2003-07-31 Gruenenthal Gmbh Verwendung von (+)-(1S,2S)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol als Antiemetikum
DE102005013726A1 (de) * 2005-03-22 2006-09-28 Grünenthal GmbH Transdermale therapeutische Systeme mit verbesserter Verträglichkeit
GB0506800D0 (en) * 2005-04-04 2005-05-11 Merck Sharp & Dohme New uses
US8551986B2 (en) * 2005-12-08 2013-10-08 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
JP5433236B2 (ja) 2006-01-27 2014-03-05 アプタリス ファーマテック，インコーポレイテッド 弱塩基性選択性セロトニン５−ｈｔ３遮断剤および有機酸を含む薬物送達系
WO2007096489A1 (fr) * 2006-02-17 2007-08-30 Trimaran Limited Nouvelles compositions pharmaceutiques destinees a optimiser des traitements de substitution et elargir la pharmacopee au traitement global des addictions
US7825156B2 (en) * 2007-02-02 2010-11-02 Copharms Method of treating bipolar depression with a benzamide derivative
EP2240022B1 (en) * 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Bilayered tablets comprising oxycodone and promethazine
WO2009126931A2 (en) * 2008-04-11 2009-10-15 Xvasive, Inc. Combination therapy for bipolar disorder
GB201004020D0 (en) 2010-03-11 2010-04-21 Acacia Pharma Ltd New therapeutic use

Also Published As

Publication number Publication date
MX2012010411A (es) 2012-11-30
JP6279526B2 (ja) 2018-02-14
RS53466B (sr) 2014-12-31
US9889118B2 (en) 2018-02-13
EP2544657A2 (en) 2013-01-16
US10525033B2 (en) 2020-01-07
SI2544657T1 (sl) 2014-12-31
CN102892407A (zh) 2013-01-23
US9545426B2 (en) 2017-01-17
US20130022688A1 (en) 2013-01-24
SMT201400127B (it) 2015-05-05
HRP20140744T1 (hr) 2014-09-26
EA030335B1 (ru) 2018-07-31
ES2496092T3 (es) 2014-09-18
DK2796171T3 (da) 2018-05-07
CN102892407B (zh) 2016-03-23
BR112012022746A2 (pt) 2016-07-05
US20130022689A1 (en) 2013-01-24
SI2567690T1 (sl) 2014-12-31
PL2544657T3 (pl) 2014-10-31
EP2544657B1 (en) 2014-07-16
CY1115487T1 (el) 2017-01-04
AU2011225898A1 (en) 2012-10-04
US20200093792A1 (en) 2020-03-26
AU2011225898B2 (en) 2014-07-03
ES2496099T3 (es) 2014-09-18
EP2796171B1 (en) 2018-01-31
PL2567690T3 (pl) 2014-11-28
CA2792392C (en) 2018-06-19
MX388787B (es) 2025-03-20
PT2567690E (pt) 2014-09-03
US20170087128A1 (en) 2017-03-30
US20250186394A1 (en) 2025-06-12
EA201290833A1 (ru) 2013-09-30
SMT201800188T1 (it) 2018-07-17
JP2016028090A (ja) 2016-02-25
RS57032B1 (sr) 2018-05-31
US20210228543A1 (en) 2021-07-29
BR112012022746B1 (pt) 2021-09-28
JP2013522181A (ja) 2013-06-13
SMT201400126B (it) 2015-05-05
US20180042896A1 (en) 2018-02-15
KR101738201B1 (ko) 2017-05-19
US20220296570A1 (en) 2022-09-22
NZ602279A (en) 2014-08-29
RS53467B (sr) 2014-12-31
US9084765B2 (en) 2015-07-21
EP2567690B1 (en) 2014-07-16
GB201004020D0 (en) 2010-04-21
US12194022B2 (en) 2025-01-14
US8686019B2 (en) 2014-04-01
MX370629B (es) 2019-12-18
CY1115485T1 (el) 2017-01-04
DK2544657T3 (da) 2014-08-11
CY1120170T1 (el) 2018-12-12
SI2796171T1 (en) 2018-05-31
CA2792392A1 (en) 2011-09-15
US20180353473A1 (en) 2018-12-13
WO2011110854A2 (en) 2011-09-15
MX2019015396A (es) 2020-02-07
ES2665418T3 (es) 2018-04-25
US10085970B2 (en) 2018-10-02
EP2567690A1 (en) 2013-03-13
HUE037088T2 (hu) 2018-08-28
EP2796171A1 (en) 2014-10-29
HRP20180436T1 (hr) 2018-05-04
NO2796171T3 (da) 2018-06-30
US20230144973A1 (en) 2023-05-11
KR20130045241A (ko) 2013-05-03
US20150335616A1 (en) 2015-11-26
US9119836B2 (en) 2015-09-01
PT2544657E (pt) 2014-09-03
HK1179152A1 (zh) 2013-09-27
IL221746A (en) 2017-03-30
HRP20140745T1 (hr) 2014-09-26
PT2796171T (pt) 2018-04-24
JP5886213B2 (ja) 2016-03-16
LT2796171T (lt) 2018-05-10
US20140147517A1 (en) 2014-05-29
PL2796171T3 (pl) 2018-07-31
WO2011110854A3 (en) 2011-11-10

Similar Documents

Publication Publication Date Title
HUE037088T2 (hu) Amiszulpirid ópiát-okozta hányinger és hányás terápiájában való alkalmazásra
DK2632954T4 (da) Midler og fremgangsmåder til behandling af dlbcl
DK3494972T3 (da) Kombinationer af dolutegravir og lamivudin til behandling af HIV-infektion
DK2663254T3 (da) Fremgangsmåder, systemer og tilbehør, der kan anvendes til procedurer vedrørende tandimplantater
DK2498771T3 (da) Anvendelse af bethanechol til behandling af xerostomi
DK3622883T3 (da) Indførerer til medicinsk indretning og fremgangsmåder til at indføre og anvende medicinske indretninger
DK2594140T3 (da) Nanopartikler til indkapsling af forbindelser, fremstilling og anvendelse deraf
DK2594567T3 (da) Heterocykliske alkynylbenzenforbindelser og anvendelser deraf
DK2462116T3 (da) Fremgangsmåde til fremstillingen af farmaceutisk aktive forbindelser
DK3251678T3 (da) Benzoxaborolderivater til behandling af bakterieinfektioner
DK2270818T3 (da) Polyelektrolyt og fremgangsmåde til fremstilling af polyelektrolytten
DK3382015T3 (da) Fremgangsmåder og produkter til fremstilling af voksestere
DK2445912T3 (da) Ny forbindelse anvendelig til behandlingen af degenerative og inflammatoriske sygdomme
DK2585362T3 (da) Forbindelseslåseenhed og fremgangsmåde
DK3661211T3 (da) Billedforudsigelse-afkodningsfremgangsmåde
DK2600715T3 (da) Flydende ST-246-formuleringer og fremgangsmåder
DK3246042T3 (da) Lægemiddelresistent immunterapi til behandling af cancer
DK2542373T3 (da) Svejset, lamineret anordning, fremstillingsfremgangsmåder og fremgangsmåder til anvendelse af anordningen
DK2567173T3 (da) Anordning og fremgangsmåde til lagring af varme
DK2642992T3 (da) Forbindelser og anvendelse deraf
DK2549995T3 (da) Brug af anatabin til behandling af inflammation og metoder til syntetisering af anatabin
DK2889365T3 (da) Fremgangsmåde til undersøgelse af mikroorganismer og indretning dertil
DK2780059T3 (da) Medicinsk anordning og fremgangsmåde til begrænsning af anvendelsen af den medicinske anordning
DK2536399T3 (da) Fremgangsmåde til aktivering og konjugering af biomolekyler
DK2455064T3 (da) Indretning til behandling af periodontal sygdom